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Abstract
Background: Despite successes in preventing and treating HIV, Indigenous people in Canada continue to face
disproportionately high rates of HIV infection. Programs that support healing from lifetime trauma, support
connection to culture, and reduce drug-related harms are critical to preventing HIV among young Indigenous
people who use drugs. The Cedar Project WelTel mHealth intervention proposed here is a structured mobile-phone
initiative to connect young Indigenous people who use drugs with Cedar Case Managers in a community-based
setting. The intervention consists of a package of supports, including a mobile phone and cellular plan, weekly
two-way text messaging, and support from Cedar Case Managers.
Methods: The Cedar Project WelTel mHealth study is a multi-site Zelen pre-randomized trial to measure the effect
of a two-way supportive text-message intervention to reduce HIV vulnerability among young Indigenous people
who use illicit drugs in two Canadian cities. The trial is nested within the Cedar Project, an ongoing cohort study
addressing HIV and hepatitis C vulnerability among young Indigenous people who use drugs in Vancouver and
Prince George, British Columbia. The Cedar Project Partnership, an independent body of Indigenous Elders, leaders,
and health/social service experts, governs all aspects of the study. Two hundred participants will be followed over a
16-month period, with HIV propensity score at 6 months as the primary outcome. Secondary outcomes include HIV
propensity at 1 year, HIV risk, resilience, psychological distress, access to drug-related services, and connection to
culture measured at 6 months and 1 year. Primary analysis is by intention to treat.
Discussion: Culturally safe interventions that address barriers to HIV prevention while supporting the strength of
young Indigenous people who use drugs are urgently needed. Despite presenting a tremendous opportunity to
connect young, highly transient Indigenous people who use drugs to prevention services, supportive two-way
mHealth programs have yet to be tested for HIV prevention in a community-based setting with this population.
Trial registration: ClinicalTrials.gov NCT02437123 https://clinicaltrials.gov/show/NCT02437123 (registered 4 May 2015).
Protocol version: 24 July 2015.
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Background
Indigenous scholars suggest that understanding substance
use and HIV vulnerability among young Indigenous
people must begin with consideration of the ongoing im-
pact of colonization and intergenerational trauma while
also acknowledging strength and survival in the face of in-
credible hardships [1–5]. Indigenous scholars have de-
scribed intergenerational trauma as a collective emotional
and psychological “soul wound” that continues to affect
the youngest generations of Indigenous people [6, 7]. In
Canada, well over 150,000 Indigenous children were for-
cibly removed from their homes and placed in residential
schools between 1883 and 1996 [8]. The persistent devalu-
ation of Indigenous cultural identity and widespread
physical, sexual, and emotional abuse that occurred at
residential schools has had far-reaching consequences for
the health of Indigenous people [9]. Many Indigenous
scholars and advocates argue that cultural oppression
through the removal of children from their families and
communities has continued through the child welfare sys-
tem [10]. In fact, estimates indicate that three times as
many Indigenous children are currently in care of the state
compared with during the peak of the residential school
system in the 1940s [10]. In a study of young Indigenous
people who use drugs in British Columbia (BC), 65 % had
been removed from their biological parents and placed
into care [11]. Those who had been in care were 2.1 times
more likely to have a parent who attended residential
school and 2.6 times more likely to have been sexually
abused. The residential school and child welfare systems
in Canada disrupted ways of life that had sustained Indi-
genous families and communities over generations, and
introduced cycles of multi-generational grief, trauma, and
displacement [10]. Acknowledging the profound effect of
intergenerational and lifetime trauma, and subsequent re-
liance on the powerful numbing effect of drugs, is critical
to understanding HIV vulnerability among young Indigen-
ous people who use drugs [4, 7, 12–15].
Indigenous leaders in Canada are justifiably concerned
about alarming rates of HIV infection among their young
people who continue to be vastly over-represented in the
HIV epidemic [16]. Although Indigenous people comprise
just 3.8 % of Canada’s total population, Indigenous people
in 2013 represented 16 % of positive HIV tests in the
country [17]. Injection drug use remains the primary ex-
posure among Indigenous people, accounting for 64 % of
HIV infections, compared with 11 % among non-
Indigenous people [16]. In addition, one third of new in-
fections were among young Indigenous people under
30 years of age, compared with only 20 % among young
non-Indigenous people [16]. There is a continuing crisis
of HIV infection among young Indigenous people who
use injection and non-injection drugs in BC; HIV preva-
lence reached 9 % overall and 17 % among those who
inject drugs [12]. In addition, HIV incidence among young
Indigenous people who use injection drugs in BC is esti-
mated to be three times higher than among non-
indigenous young people [18].
Significant and multi-layered barriers to HIV prevention
services, including health care, harm reduction, addiction
treatment, and safer sex work environments, have been
identified among young Indigenous people who use drugs
[2, 3, 12, 13]. Young Indigenous people who use drugs
have described frequent encounters with systemic and
interpersonal racism, stigma and judgement within harm
reduction and health services [1, 19–23]. Furthermore,
despite compelling evidence that harm reduction pro-
grams, including supervised drug consumption facilities
[24] and opioid substitution therapy [25], are effective at
preventing HIV infection, studies indicate that young Indi-
genous people are failing to engage with these services
[12, 18, 26, 27]. Finally, safety in sex work, as well as sup-
ports to leave sex work if desired, remains elusive in a
country where young Indigenous women in sex work rou-
tinely face extreme violence and death in the course of
their work [28, 29].
Addressing barriers to HIV prevention among young
Indigenous people who use drugs—while also acknow-
ledging resilience despite adversity—is urgently required.
In New Zealand, Maori nurses have emphasized the
need for health care that is “culturally safe” in order to
overcome power imbalances that shape interactions be-
tween health-care providers and Indigenous clients [30].
Culturally safe care simultaneously privileges Indigenous
worldviews and acknowledges the impact of structural
violence experienced by colonized peoples in health-care
settings [31]. Indigenous experts also recognize the
importance of “culture as intervention” to support resili-
ence and resistance to HIV infection as well as trauma-
informed counseling as a response to the harmful effects
of historical and lifetime trauma [1]. Others have noted
the critical role of interconnectedness with family and
community to support health and healing among Indi-
genous individuals [32]. Further research has highlighted
the importance of non-medical, supplementary support
for young Indigenous people in order to break through
layers of marginalization experienced in their everyday
lives [33].
Mobile health (mHealth), the provision of health care
via mobile phones, has been identified as potential tool
to support young drug-using Indigenous people to over-
come barriers to HIV prevention. Recent trials in sub-
Saharan Africa have provided evidence that supportive
text-message interventions can improve HIV treatment
adherence and viral suppression among people living
with HIV [34, 35]. Others have begun to investigate the
impact of mHealth for HIV care and treatment among
people living with HIV who use drugs [36–38]. However,
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much of the existing evidence on mHealth interventions
for HIV prevention has focused on improving HIV
knowledge by delivering HIV prevention messages to di-
verse at-risk groups [39]. To our knowledge, no studies
have investigated the potential for a two-way supportive
text-message program to reach out to young drug-using
Indigenous people to reduce vulnerability to HIV
infection.
This protocol outlines a multi-site Zelen pre-randomized
trial to measure the effect of a culturally safe, two-way sup-
portive text-message intervention to reduce HIV vulnerabil-
ity among young Indigenous people who use illicit drugs.
This work will build on findings from recent studies imple-
menting mHealth interventions in HIV clinics in Nairobi,
Kenya and Vancouver, Canada [34, 40]. Outcomes include
HIV propensity score, HIV risk, resilience, psychological
distress, access to drug-related services, and connec-
tion to culture. We hypothesize that the Cedar Project
WelTel mHealth intervention will result in improved up-
take and access to HIV prevention services, including
health-care, harm reduction and addictions services, cul-
tural supports, housing, and counseling. We believe that,
together with the supportive element that “someone
cares” enough to check in each week, improved access to
services will help strengthen participants’ resilience and
reduce vulnerability to HIV infection.
Methods and design
Study design
The Cedar Project WelTel mHealth study is a two-site,
two-arm, parallel group, open, stratified Zelen pre-
randomized controlled trial to measure the effect of a cul-
turally safe, two-way supportive text-message intervention
to reduce HIV vulnerability among young Indigenous
people who use illicit drugs in a community-based setting
(ClinicalTrials.gov identifier NCT02437123). Participants
will be pre-randomized to two groups—either the mHealth
intervention or standard care—at a 1:1 allocation ratio.
Study setting
This trial is a sub-study nested within the Cedar Project,
a cohort study of young Indigenous people who use in-
jection and non-injection drugs and reside in Vancouver
and Prince George, BC, Canada. Initial recruitment into
the Cedar Project occurred between 2003 and 2007 and
was re-opened in 2011. To date, 738 participants have
enrolled in the main Cedar Project cohort in Vancouver
and Prince George. Eligibility criteria included being be-
tween the ages of 14 to 30 at enrollment, provision of in-
formed consent, self identification as having Indigenous
ancestry, and smoking or injecting drugs—including
crystal methamphetamine, opiates, crack or cocaine—at
enrollment. Cedar Project participants complete an en-
rollment visit as well as follow-up visits every 6 months.
At each study visit, participants complete detailed ques-
tionnaires eliciting demographic, behavioural and health
information, administered by trained Indigenous inter-
viewers. Participants also provide a venous blood sample
for HIV and hepatitis C virus antibody testing. In grati-
tude for participants’ time, honoraria are provided at
each follow-up visit. The Cedar Project has been ap-
proved by the University of British Columbia Providence
Health Care Research Ethics Board (H02-50304).
The Cedar Project study storefront research offices are
located in Vancouver’s downtown eastside and in the
downtown core of Prince George. Vancouver is a large city
in southern BC and is located on the traditional territory
of the Coast Salish peoples. Prince George is a forestry
and mining town in the province’s northern interior, lo-
cated on the traditional territory of the Lheidli T’enneh
people. Cedar Project participants represent many of the
diverse First Nations, Inuit and Métis communities across
Canada and are often living far away from their home
communities. Participants are highly transient, moving
frequently between cities and reserves, making continuity
of care a tremendous challenge [41]. Indigenous inter-
viewers and nurses support both sites and are encouraged
to provide referrals to cultural supports, health care, sub-
stance use services, food programs, housing, and counsel-
ing for participants who seek them.
The Cedar Project Partnership model
Since its inception, the Cedar Project has been
community-driven, interdisciplinary research that re-
sponds to the continuing crisis of HIV infection and con-
tributes to the health and healing of young Indigenous
people who use drugs. The Cedar Project Partnership, an
independent body of Indigenous Elders, health and social
service experts, researchers, and elected leaders, governs
the entire research process. The Cedar Project Partnership
recognizes that conducting culturally safe research with
young, vulnerable Indigenous people requires creating safe
spaces where their identities, voices and stories are heard
and respected [30]. A critical component of the Cedar
Project is to ensure that our site offices are safe, welcom-
ing settings without judgement of drug use, where police
are not allowed, and cultural identity is honoured. Part of
building cultural safety into the Cedar Project includes
supporting access to traditional foods and ceremonies,
such as through annual feasts, memorials, and a recent
Learning Potlatch to honour our partners and participants
held in Prince George. Overall, our paradigm is to ac-
knowledge grief and historical trauma while building on
young Indigenous peoples’ strengths.
Participants
A stratified random sample of participants in the Cedar
Project cohort will be selected for participation in the
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Cedar Project WelTel mHealth study (Fig. 1). A sam-
pling frame of eligible Cedar Project participants will be
created on the basis of the following eligibility criteria:
(1) Currently enrolled in the Cedar Project
(2) Completed main Cedar Project baseline
questionnaire and attended at least one follow-up
visit since 2009
(3) Had not tested positive for HIV
(4) Joined study in Vancouver or Prince George
(5) Alive at initiation of the Cedar Project WelTel
mHealth study.
Participants who do not meet the eligibility criteria or
who decline to participate will be excluded. Stratified
randomization in a 1:1 ratio will be used to ensure a bal-
ance of key factors, including study site (Prince George
and Vancouver) and reporting injection drug use at the
last visit (yes versus no). Sampled participants will be
randomly assigned to receive the intervention or be
Assessed for eligibility
(n = 738)
Excluded as did not meet 
inclusion criteria (n = 388)
Randomized (n = 240)
Allocated for invitation 
into intervention
(n = 140)
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Fig. 1 Cedar Project mHealth Study for HIV prevention CONSORT diagram of study design
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included in the comparison group through computer-
generated codes developed by a statistician at the Centre
for Evaluation and Outcome Sciences at St. Paul’s Hospital.
A list of participants to be invited into the intervention arm
will be distributed to each study site. Informed consent will
be sought from each participant invited to receive the inter-
vention who agreed to participate. Those assigned to the
comparison group will continue in the usual Cedar Project
cohort study under its existing informed consent with no
change whatsoever to their participation in the overall
study. Target enrollment is set at 200 participants.
Intervention group
To ensure that we reach our target sample, initial
randomization will be slightly unbalanced to accommo-
date refusals to participate or difficulty locating partici-
pants. A total of 140 participants (70 from each site) will
be randomly allocated to receive the invitation to partici-
pate in the intervention arm of the mHealth study. This
will allow for an estimated 20 participants per site who
cannot be reached or who decline to participate. Cedar
staff will invite and enroll participants from this list to
join the study until enrollment reaches 50 at each study
site. Three attempts will be made to invite participants
in the intervention arm into the study, including during
regular visits to the research offices, phone, email, word
of mouth, and street outreach.
Comparison group
One hundred Cedar Project participants who meet the
eligibility criteria will be allocated to serve as the cohort
comparison group, stratified on the same variables used
to select the intervention group. Participants randomly
assigned to the control group will continue as Cedar
Project participants under usual circumstances. This
group of cohort controls will not be required to provide
any additional data to the study beyond that which they
provide in semi-annual follow-up interviews as partici-
pants in the main Cedar Project study.
The intervention
The Cedar Project WelTel mHealth intervention being
evaluated is a structured mobile-phone initiative to connect
young Indigenous people who use drugs with Cedar Case
Managers in a community-based setting. The intervention
consists of a package of supports, including a mobile phone
and cellular plan, weekly two-way text messaging, and sup-
port from Cedar Case Managers. The intervention will be
implemented over a 16-month period, and all participants
will receive the intervention for a minimum of 6 months.
Cedar Case Managers include Indigenous and non-
Indigenous nurses and Cedar Project staff members who
have extensive frontline outreach experience with young
Indigenous people who use drugs in Prince George and
Vancouver. Cedar Case Managers follow a “culturally
safe” approach that acknowledges both trauma and
strengths and includes an explicit focus on the critical
roles of cultural assets and safe relationships with care
providers in HIV risk reduction [31].
Participants allocated to receive the intervention will
be provided with a cellular phone at the start of the
study. Each phone is pre-programmed with several
phone numbers for emergency and health-related ser-
vices relevant to the study site. During the study period,
participants will receive a monthly cellular plan that in-
cludes unlimited calling and texting within Canada, but
no data. We made an explicit decision to include long-
distance calling and texting to provide the opportunity
for participants to connect with family and loved ones
living in home communities and elsewhere in Canada. If
phones are lost or stolen, participants will be eligible to
receive one replacement. If two phones are lost, the par-
ticipant may bring their own sim card-enabled cellular
handset to use with the study monthly cellular plan.
The supportive text-message component of the study is
based on the intervention tested in the WelTel Kenya1
trial (Fig. 2) [34]. Each Monday at noon, a text message
saying, “How’s it going?” is automatically sent to interven-
tion arm participants through the WelTel mHealth soft-
ware platform. Cedar Case Managers will login within 24
to 48 hours to triage the incoming text messages. They
will respond to all participants and follow up with partici-
pants who replied with a specific problem or need. On
Wednesday, participants who have not replied will receive
an additional text saying, “Haven’t heard from you, are
you OK?” On Thursday or Friday, staff will attempt
to call all remaining participants who have not
text message at 
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Fig. 2 The Cedar Project WelTel mHealth intervention
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responded by text message. Throughout, study staff
will keep a log of all responses and actions taken
through the WelTel platform.
Blinding
We recognize that blinding in a trial such as ours is
challenging. Care providers (Cedar Case Managers) and
intervention arm participants cannot be blinded, as the
mHealth intervention requires overt participation and
an “invite list” is provided upfront. However, participants
in both the intervention and control groups will be
blinded to specific study hypotheses. Primary and sec-
ondary outcomes will be drawn from routine data collec-
tion that occurs as part of participation in the overall
cohort; it is unlikely that participants will identify the
specific questions used to generate outcomes from our
extensive questionnaires. The data analyst will also be
blinded to group allocation.
Objectives
The study’s primary objective is to test whether the
Cedar Project mHealth intervention reduces vulnerabil-
ity to HIV among young Indigenous people who use
drugs, measured by using an HIV propensity score de-
scribed below. Our secondary objectives are to test the
specific ways the mHealth intervention may reduce vul-
nerability to HIV by exploring HIV risk behaviours, re-
silience, psychological distress, access to drug-related
services, and connection to culture among participants
over the course of the study.
We hypothesize that participants receiving the inter-
vention will seek help from Cedar Case Managers to
navigate barriers to drug-related services, housing, cul-
tural supports, and health care. Also, we hypothesize
that participants will use the phones as tools to connect
with other supports and sources of strength in their
lives, including family, work, culture, and services. Thus,
we hypothesize that the intervention will help young
people to work towards goals related to their own health
and well-being, supporting them to reduce HIV risk.
Outcome measures
Primary outcomes
The primary outcome (Table 1) is HIV risk, measured
by an HIV propensity score assessed at the 6-month
time point. Previous analyses of Cedar Project data with
respect to HIV infection have identified several factors
as associated with HIV infection, including recent injec-
tion drug use, high-frequency drug use, needle sharing,
and participation in sex work [12]. Logistic regression of
risk factors for prevalent HIV infection at study recruit-
ment will provide coefficients to combine these four risk
variables into a single primary outcome measuring pro-
pensity for HIV infection. Mean change in HIV propensity
score from baseline to 6 months will be used to determine
the impact of the intervention on HIV vulnerability.
Secondary outcomes
The potential benefits of the supportive mHealth inter-
vention are broad. As a result, multiple secondary out-
comes are of interest. These were selected through
consultation with academic and community partners
and are part of routine Cedar Project data collection.
They fall under five categories: HIV risk, resilience, psy-
chological distress, access to drug-related services, and
connection to culture. For all secondary outcomes, the
effect of the mHealth intervention will be measured as
change in the outcome from baseline to 6 months. Par-
ticipants with sufficient follow-up time will contribute to
analyses of all outcomes at the 1-year time point to de-
termine longer-term effects of the intervention.
HIV propensity (12 months) Participants who received
the intervention for a sufficient length of time will con-
tribute to a secondary analysis of change in HIV propen-
sity at 1 year to determine longer-term effects of the
Cedar Project WelTel mHealth intervention. The HIV
propensity variable will be generated by using the same
approach used for the primary outcome.
HIV vulnerability Although the effect of the intervention
on HIV risk will be assessed in the primary analysis, we
will also analyze the effect of the intervention on specific
behaviours. Several self-reported binary measures will be
used to determine the effect of the intervention on HIV
vulnerability in the previous 6-month period, including in-
jection drug use in the past 6 months, high-frequency
(daily or more) drug use, needle sharing, and participation
in sex work. These measures will be ascertained from
Cedar Project questionnaires collected every 6 months as
part of the main Cedar Project cohort. HIV vulnerability
will be assessed at baseline, 6 months, and 1 year.
Resilience Resilience, or the ability to cope with adver-
sity, will be characterized by using the Connor-Davidson
Resilience Scale (CD-RISC). The creators of the scale
broadly define resilience as “personal qualities that en-
able one to thrive in the face of adversity” [42]. The CD-
RISC scale measures resilience via 25 items on a five-
point scale with scores ranging between 0 and 100, with
higher scores indicating greater resilience. Resilience will
be assessed at baseline, 6 months, and 1 year.
Psychological distress The Symptom Checklist-90-R
(SCL-90-R) is a 90-item self-reported symptom inventory
that measures the severity of nine dimensions of psycho-
logical distress in the past 3 months scored on a five-point
Likert scale (from ‘not at all’ to ‘extremely’). Participants’
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SCL-90-R scores will be transformed into an average
Global Severity Index, providing a single average measure
that profiles overall degree of psychological distress [43].
Psychological distress will be assessed at baseline,
6 months, and 1 year.
Access to drug-related services Self-reported access to
drug-related services, including opioid substitution ther-
apy, needle exchange, safe injection facility, and drug
treatment, in the previous 6-month period, will be ascer-
tained from the main Cedar Project questionnaire. Pro-
portions of participants reporting access to these
services will be compared in the intervention and con-
trol groups. We will also determine whether there are
differences among treated and control groups in terms
of proportion of people who tried to quit in the previous
6-month period. Access to drug-related services will be
assessed at baseline, 6 months, and 1 year.
Connection to culture Connection to Indigenous cul-
ture has been hypothesized as a key protective factor for
young Indigenous people who use drugs. It will be
assessed by using two dichotomous variables that meas-
ure cultural activity in the prior 6-month period: (1)
self-reported participation in traditional ceremonies (in-
cluding potlatch, feast, fast, burning ceremony, washing
ceremony, naming ceremony, big/smoke house, rites of
passage, smudge, dances, or any other traditional Indi-
genous ceremony) and (2) frequency living by traditional
culture (never/rarely versus often/always). These vari-
ables were defined by Earl Henderson (Cree, Métis) and
Violet Bozoki (Lheidli T’enneh) who are Indigenous
Elders, traditional knowledge keepers, and members of
the Cedar Project Partnership.
Sample size
Considering current follow-up rates, we are likely able to
reach and recruit at least 200 participants for participation
in both arms of the Cedar Project WelTel mHealth study.
As mentioned previously, the primary objective is HIV
risk, measured by using an HIV propensity score evalu-
ated at 6 months. On the basis of a 1:1 allocation ratio, a
Table 1 Outcome measures










HIV propensity score Mean change - HIV propensity score Decrease in HIV risk Continuous T test
HIV vulnerability Injection drug use Mean change - proportion injection Decrease in injection Binary χ2 test





Needle sharing Mean change - proportion needle sharing Decrease in needle
sharing
Binary χ2 test
Participation in sex work Mean change - proportion sex work Decrease in sex work Binary χ2 test
Resilience Connor-Davidson Resilience
Scale (CD-RISC)
Mean change - CD-RISC score Increase in resilience Continuous T test
Psychological distress Symptom Checklist-90-R
(SCL-90-R)







Mean change - proportion accessed OST Increase in access OST Binary χ2 test
Needle exchange (NX) Mean change - proportion attended NX Increase in access NX Binary χ2 test
Safe injection facility (SIF) Mean change - proportion visited SIF Increase in access SIF Binary χ2 test












Mean change - proportion participated in
traditional ceremony
Increase in access to
ceremony
Binary χ2 test
Frequently living by traditional
culture





All variables refer to behaviour in the 6-month period preceding the interview. All variables are measured as mean change in proportion or score from baseline
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significance level of 0.05 (one-sided) and 80 % power, it is
estimated that we require 78 participants in each study
arm. This computation assumes a standardized mean ef-
fect size (using Cohen’s d) of 0.40. Assuming attrition
rates of approximately 20 %, we intend to over-enroll,
resulting in a target of 200 participants overall (100 in
each arm). Sample size was calculated by using the pwr
package in R, software version 3.2.1.
Statistical analysis
The analysis and reporting of the results will follow the
CONSORT (Consolidated Standards of Reporting Trials)
guidelines [44]. Descriptive statistics of socio-demographic,
historical/lifetime trauma, sex- and drug-related HIV vul-
nerabilities, and health-related variables will be presented
to assess comparability of the intervention and control
groups. Mean (standard deviation) or median (quartiles)
will be used for continuous variables and count (percent-
age) for categorical variables. Our primary analysis to evalu-
ate the effect of the mHealth intervention on HIV
prevention will be by intention to treat (ITT) for primary
and secondary outcomes among all randomly assigned par-
ticipants according to the study group to which they were
originally allocated. Student’s t tests and chi-squared tests
will be used to determine differences in the mean change in
proportions or scores from baseline at 6 months or 1 year
between the two study arms. If baseline characteristics are
found to be substantially different between the two study
arms, we will adjust for these factors by using regression
models. In addition, we will conduct a secondary analysis
by using a modified ITT approach including only partici-
pants who agreed to participate in the intervention making
up the intervention group (excluding over-sampled partici-
pants who did not receive the intervention). To minimize
the risk of bias introduced in our modified ITT analysis, we
propose to use complier average causal effect (CACE) ana-
lysis [45]. This approach will allow us to retain the initial
random assignment by taking into account two subgroups
within the group pre-randomized to receive the interven-
tion (those who did and did not actually receive the inter-
vention) and then helping us to identify a similar subgroup
of control participants who could have been expected to re-
ceive the intervention had it been offered [45]. By compar-
ing expected and observed outcomes in these subgroups,
we will obtain a less biased estimate of effect of the inter-
vention [45]. Missing data will be approached by using mul-
tiple imputation. An up-to-date version of R statistical
software will be used to conduct all analyses [46]. All tests
will be two-sided; P values of less than 0.10 will be consid-
ered significant. We plan to conduct four predetermined
exploratory subgroup analyses that may help to tailor the
intervention for specific high-need populations, including
comparisons by gender, city, injection drug use, and urban
versus rural. Statistical methods similar to those described
above for whole-group analyses will be conducted for pri-
mary and secondary outcomes. All subgroup results will be
reported, regardless of significance. Inferences will be
hypothesis-generating, given concerns related to multiple




As this study is the first of its kind in a community-
based setting among young Indigenous people who use
drugs, it is critical that the implementation of the inter-
vention be described in detail. Daily mHealth memos
prepared by each study site, combined with procedural
documents, will inform a description of how a support-
ive two-way text-message program looks and functions
in practice. Descriptive statistics generated from the
mHealth baseline questionnaire will provide additional
insight into the feasibility of applying this program in
similar settings. The survey asks about ownership and
use of mobile phones, how often participants text mes-
sage, and perceived helpfulness or concerns about re-
ceiving text messages related to health.
Types of support requested
Examining the types of support requested by Cedar Pro-
ject WelTel mHealth participants via text will help to
identify current challenges accessing prevention services
and support among young Indigenous people who use
drugs. A comparative content analysis of text-message
interactions captured on the WelTel platform over the
study period will be used for this purpose. This descrip-
tive analysis will help inform scale-up of this program,
including the human resource requirements for future
implementation in similar settings.
Participant perceptions
Participant perceptions of the mHealth intervention will
be evaluated via the mHealth follow-up questionnaire.
All intervention arm participants will be invited to
complete an administered questionnaire to assess satis-
faction with the care and support they received via the
intervention. Evaluation of patient perceptions will in-
clude thematic analysis of narrative responses and basic
descriptive statistics.
Ethics
The Cedar Project follows the guidelines provided in the
Tri-Council Policy Statement on Ethical Conduct for Re-
search Involving Humans – Chapter Nine: Research involv-
ing the First Nations Inuit and Métis Peoples of Canada
[47]. In addition, the study will adhere to the principles of
Ownership, Control, Access and Possession in relation to
research with Indigenous people [48]. Through the Cedar
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Project Partnership, Indigenous collaborators will continue
to be involved in the conception, design and interpretation
of the results of the Cedar Project WelTel mHealth study.
The Cedar Project Partnership will serve as the data and
safety monitoring board for this study. They have also ap-
proved this manuscript for publication. The Cedar Project
WelTel mHealth study has been approved by the University
of British Columbia Providence Health Care Research
Ethics Board (H13-02718), and we will be accountable to
them for approval and monitoring.
All participants have provided informed consent as
part of the main Cedar Project cohort study. Participants
randomly assigned to receive an invitation to participate
in the Cedar Project WelTel mHealth intervention will
undergo an additional consent process. After the study
participant is invited to participate in the Cedar Project
WelTel mHealth study, a trained Cedar Project staff
member will describe the study. If the person would like
to enroll, the research staff will review the consent form
and answer any questions. Participants who give consent
are provided with a copy of the study introduction letter
and consent form.
Harms
Adverse events will be documented in writing and re-
ported to investigators. Study staff at both sites have been
trained in recognizing and reporting of adverse events, in-
cluding those directly attributable to the intervention (e.g.,
accidental disclosure of illicit drug use) and those resulting
from trial participation. Because the study takes place in a
community-based (not clinical) setting, staff will make re-
ferrals to care where appropriate. Potential harms will be
outlined to participants during the informed consent
process. All unanticipated risks to human participants or
others will be reported to the Cedar Project Partnership
and the University of British Columbia/Providence Health
Care Research Ethics Board where appropriate.
Dissemination
Knowledge translation is a hallmark of the Cedar Project
and will be a key component of the Cedar Project WelTel
mHealth study. Integrated knowledge translation is
planned throughout the study, and updates will be pro-
vided to the Cedar Project Partnership at quarterly meet-
ings. Findings will be shared through ceremony with
Indigenous partners; peer-reviewed publications and pre-
sentations; and consultations with policy makers and ser-
vice delivery organizations to support uptake of results.
Discussion
Innovative, culturally safe interventions that address the
barriers to HIV prevention while supporting the strength
of young Indigenous people who use drugs are urgently
needed. This study, due to report its findings in 2017,
tests the effectiveness of a two-way supportive text-
message program delivered in a community-based setting
to support HIV prevention among young Indigenous
people who use drugs. Despite presenting a tremendous
opportunity to connect young, highly transient Indigenous
people who use drugs to prevention services and support,
supportive two-way mHealth programs have yet to be
tested for HIV prevention in a community-based setting
with young Indigenous people who use drugs [34, 49–51].
Other researchers have used two-way supportive messa-
ging interventions to engage people living with HIV in
care and to improve adherence [34, 36, 40, 52, 53]. Recent
randomized controlled trials in Kenya indicated that intro-
ducing mobile-phone technology into HIV case manage-
ment improved HIV treatment adherence and HIV-
related clinical outcomes, despite high levels of poverty,
remote and rural living, transience, stigma, and discrimin-
ation [34, 50, 54]. These studies have demonstrated the
importance of text-message programs that are both sup-
portive and interactive [35, 55–57], as passive mHealth
programs that seek to monitor, remind or educate have
had limited success [58–60]. It is important to note that
we have deliberately chosen an open-ended weekly text
message to allow participants to set their own priorities
around their health and well-being, as well as to avoid
possible disclosure of drug use and other sensitive issues.
We have chosen a cohort-embedded Zelen pre-
randomized controlled trial design [61–63]. Our ongoing
Cedar Project cohort study provides the opportunity to
support recruitment into the embedded trial and also al-
lows us to use routinely measured outcomes collected lon-
gitudinally among the whole cohort. All participants
entering the cohort have consented to providing observa-
tional data. Consent to “try” the intervention is being
sought only from those who have been pre-randomized to
receive the intervention [63]. Study outcomes among
randomly selected participants will be compared with those
of the cohort members not randomly selected to receive
the intervention. Another advantage of this design is to
minimize false hopes, resentment, and contamination
among controls had they learned they were not receiving a
potentially valued intervention through trial consent and
randomization [61, 62]. In our instance, as it is not possible
to completely separate intervention participants from the
rest of the cohort, it is likely that some members of the co-
hort will come to know about the intervention. However,
even if control participants have or obtain a phone and cel-
lular plan, full crossover of participants from control to
intervention is not possible, owing to the nature of the
intervention. As noted above, neither group will be aware
of the hypotheses under study. A limitation of this design is
that a significant number of participants allocated to the
intervention arm may refuse to receive it whereas control
subjects do not have this option. Including the former
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group in an ITT analysis may dilute the treatment effect,
whereas excluding them could lead to a biased comparison.
In our case, we believe that the intervention is likely to be
highly valued among invitees and there will be few who re-
fuse. Nevertheless, this will be monitored closely, and as
noted earlier, we will also use a modified ITTapproach.
A key component of the Cedar Project WelTel mHealth
study is relational accountability [64]. We honour our rela-
tionships with study participants who have continued to
share their stories with us since joining the Cedar Project.
Testing this intervention is a way for us to respond to the
clear message from Cedar Project participants about the
importance of having support to navigate barriers to care
and services that they face in their daily lives. An additional
component of our relational accountability is through the
governing leadership of the Cedar Project Partnership, who
work to ensure that this research is relevant to the commu-
nities they represent and is conducted in a good way.
Limitations
Our decision to over-sample in the intervention arm to
adjust for refusals to participate or difficulty locating
participants may result in a dilution of the effect of the
intervention in ITT analysis. As a result, we have pro-
posed a parallel, modified ITT analysis, which may be af-
fected by selection bias. Diversity of HIV risk among
participants (non-homogeneity) may also dilute the de-
tected effect of the intervention. Representativeness of
the sample is dependent on representativeness of the
Cedar Project cohort study sample overall; however, we
have made a considerable attempt to ensure that the
sample represents the population under study [12]. As
this study involves a package of support that includes
mobile phones, two-way text messaging, and support, it
is difficult to determine the relative contribution of com-
ponents of the package to any effect the intervention
may have. The qualitative nested studies will help in this
regard. Furthermore, we cannot rule out that simultan-
eous co-interventions could impact our results. As BC’s
HIV incidence has been stable for several years and many
public health initiatives (including needle exchanges and
safe injection sites) are already in place, we feel it is un-
likely that new transformative co-interventions will take
effect over the study period. However, we will monitor po-
tential co-interventions that could impact study outcomes
through our main cohort questionnaires, as well as track
major policy and programmatic changes in the Province.
Blinding in this study is not possible as assessors have
strong relationships with participants. In addition, loss to
follow-up may be higher in the comparison group than
the intervention group. Cedar Project participants are
highly transient and often difficult to track down [41].
Having a mobile phone and consistent airtime will likely
make it easier to reach participants receiving the
intervention for follow-up visits. Active follow-up with all
participants through phone, email, and outreach will help
ensure retention and interview appointment attendance.
In addition, our measures may not adequately capture
complex concepts such as connection to culture and re-
silience. Finally, the intervention under study is complex
and multifaceted. It may be that our proposed outcomes
do not adequately capture the impact of the intervention
on the lives of participants involved.
Trial status
Enrollment in the trial has begun but has not yet
reached full enrollment.
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